Sartorius Stedim Biotech and Repligen Corporation Partner to Introduce Perfusion-Enabled Bioreactors
A collaboration integrates Sartorius Stedim Biotech’s BIOSTAT STR bioreactors and Repligen’s XCell ATF cell-retention control technology to create simplified, scalable equipment for intensified cell culture.
Sartorius Stedim Biotech (SSB) and Repligen Corporation have entered into a collaboration agreement to integrate Repligen’s XCell ATF cell-retention control technology into SSB’s BIOSTAT STR large-scale, single-use bioreactors to create novel perfusion-enabled bioreactors, the companies announced in a Sept. 4, 2018 press release. A single control system for 50 L to 2000 L bioreactors used in perfusion cell culture applications is designed to control cell growth, fluid management, and cell retention in continuous and intensified bioprocessing and simplify the development and cGMP manufacture of biological drugs.
Through the partnership, SSB and Repligen will further collaborate to equip SSB’s recently launched ambr 250ht perfusion single-use mini bioreactor system with Repligen’s KrosFlo hollow-fiber filter technology. The bioreactor system will be sold by SSB as a complete single-use assembly. This design conserves hollow-fiber filter technology across scales, enabling users to fast-track development and scale up their cell culture perfusion processes.
Source: SSB and Repligen
FDA Approves First Treatment for Rare Lipid Storage Disease Cerebrotendinous Xanthomatosis
February 24th 2025Cerebrotendinous xanthomatosis, or CTX, is a metabolic disorder caused by a gene mutation that results in a deficiency of an important enzyme in the ability of the human body to break down fats.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
FDA Grants Full Approval for Symptomatic Tenosynovial Giant Cell Tumor Treatment
February 18th 2025Tenosynovial giant cell tumor (TGCT) is rare and non-malignant, forming in or near joints, but which if left untreated can cause damage to joints and surrounding tissue, potentially leading to significant disability.
